Affiliation:
1. Beijing Key Laboratory of Bioactive Substances and Functional Foods Beijing Union University Beijing China
2. National Center of Technology Innovation for Dairy Hohhot China
3. Intertek Health Sciences Inc. Mississauga ON Canada
Abstract
AbstractBifidobacterium infantis YLGB‐1496, originally isolated from breast milk from a Taiwanese mother, is under study for use as a probiotic. As part of safety assessment, an Ames, in vivo mouse micronucleus, and in vivo mouse spermatocyte chromosome aberration assay were conducted along with a 13‐week oral rat toxicity study. B. infantis YLGB‐1496 had no activity in any of the genotoxicity assays. Administration of the bacteria to Sprague–Dawley rats at doses ranging from 0 to 1.5 g/kg bw/day had no treatment‐related effects on any of the endpoints measured. There appear to be no concerns for translocation or pathogenicity of B. infantis YLGB‐1496 based on extensive experience with the species in general. The results of the current investigations support potential use of B. infantis YLGB‐1496 as a probiotic in infant formula.